ING Groep NV Has $44.71 Million Stock Position in DexCom, Inc. $DXCM

ING Groep NV lifted its position in DexCom, Inc. (NASDAQ:DXCM) by 33.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 673,692 shares of the medical device company’s stock after buying an additional 168,752 shares during the quarter. ING Groep NV’s holdings in DexCom were worth $44,713,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Los Angeles Capital Management LLC lifted its stake in shares of DexCom by 11.8% in the fourth quarter. Los Angeles Capital Management LLC now owns 1,811,734 shares of the medical device company’s stock worth $123,560,000 after buying an additional 191,330 shares during the last quarter. Havemeyer Place LP acquired a new stake in shares of DexCom in the fourth quarter worth $800,000. MCF Advisors LLC acquired a new stake in shares of DexCom in the fourth quarter worth $32,000. BI Asset Management Fondsmaeglerselskab A S lifted its stake in shares of DexCom by 22.9% in the fourth quarter. BI Asset Management Fondsmaeglerselskab A S now owns 67,458 shares of the medical device company’s stock worth $4,477,000 after buying an additional 12,578 shares during the last quarter. Finally, Pinebridge Investments LLC acquired a new stake in shares of DexCom in the fourth quarter worth $2,778,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on DXCM shares. Truist Financial restated a “buy” rating and issued a $80.00 price objective (down from $82.00) on shares of DexCom in a research note on Tuesday, February 17th. Citigroup restated a “buy” rating and issued a $84.00 price objective (up from $79.00) on shares of DexCom in a research note on Thursday, May 28th. Barclays reaffirmed an “underweight” rating and issued a $64.00 price target (down from $67.00) on shares of DexCom in a research report on Monday, May 18th. Sanford C. Bernstein set a $77.00 price target on DexCom in a research report on Friday, May 1st. Finally, Benchmark started coverage on DexCom in a research report on Monday, May 11th. They issued a “buy” rating and a $77.00 price objective for the company. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $82.63.

DexCom Stock Up 0.4%

DXCM opened at $72.86 on Friday. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $89.98. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42. The stock has a market capitalization of $28.11 billion, a price-to-earnings ratio of 31.14, a P/E/G ratio of 1.14 and a beta of 1.45. The business has a 50 day moving average of $64.83 and a 200-day moving average of $66.98.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, beating analysts’ consensus estimates of $0.47 by $0.09. The business had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. DexCom had a return on equity of 33.33% and a net margin of 19.31%.DexCom’s revenue was up 15.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.32 earnings per share. As a group, sell-side analysts anticipate that DexCom, Inc. will post 2.57 earnings per share for the current year.

More DexCom News

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: DexCom announced it will highlight new clinical findings, product advancements, and strategic initiatives at ADA 2026, reinforcing its case for broader CGM adoption and earlier-stage diabetes intervention. Article: Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
• Positive Sentiment: Recent commentary remained constructive, with analysts and market coverage noting DexCom’s strong Q1 momentum, global CGM growth potential, and expanding international demand, which may help support the stock. Article: Here’s Why You Should Retain DexCom Stock in Your Portfolio
• Positive Sentiment: DexCom also said it plans to acquire wellness tracking company Nutrisense and launch an enhanced Stelo app, a move that could broaden its consumer health footprint and create new engagement opportunities. Article: Dexcom to acquire wellness tracking company Nutrisense, launch enhanced Stelo app
• Neutral Sentiment: DexCom EVP Jon Coleman sold shares in two transactions under a pre-arranged 10b5-1 plan. While the sales were disclosed as routine, insider selling can still weigh on sentiment. Article: SEC Form 4 filing
• Neutral Sentiment: Separate market commentary noted DexCom has lagged the Dow over the past year, even as analysts remain bullish on its longer-term outlook. Article: Is DexCom Stock Underperforming the Dow?

Insider Buying and Selling at DexCom

In other DexCom news, Director Bridgette P. Heller sold 1,012 shares of the business’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $60.01, for a total value of $60,730.12. Following the sale, the director owned 25,007 shares of the company’s stock, valued at $1,500,670.07. The trade was a 3.89% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,759 shares of the business’s stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $72.00, for a total transaction of $1,926,648.00. Following the completion of the sale, the insider directly owned 382,482 shares in the company, valued at $27,538,704. This trade represents a 6.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 42,694 shares of company stock worth $3,029,267. Corporate insiders own 0.28% of the company’s stock.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.